MRNA Stock Jumps As FDA Clears New Flu Vaccine

Moderna Inc. stocks have been trading up by 88.06 percent on optimism over its latest positive vaccine trial data

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MRNA

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For MRNA Traders

FDA approved Moderna’s mFLUSIVA flu shot for adults 50+, its fifth global product and fourth FDA-approved therapy, with a U.S. launch aimed at the 2026–27 season and global reviews underway.
Q2 2026 showed modest revenue growth and a narrower net loss, with MRNA beating estimates but still losing $1.97 per share versus a $2.01 expected loss.
Management reaffirmed 2026 guidance for up to 10% revenue growth, trimmed cost-of-sales to $1.7B, and maintained heavy R&D at about $2.9B with $200–$300M in capex.
A key norovirus Phase 3 trial missed early success criteria, while oncology and rare disease programs, including intismeran/mRNA‑4157 with Merck, remain on track for pivotal 2026 readouts.
Citi and Goldman Sachs raised price targets on MRNA to $60 and $67 with Neutral ratings, signaling cautious optimism as Moderna shifts beyond its COVID franchise.

Live Update At 08:32:38 EDT: On Wednesday, August 19, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 88.06%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA is trading like a classic high‑beta biotech: big moves, big story, no steady profits yet. The daily chart shows a push from the mid‑$50s at the end of July up into the low‑$60s by mid‑August, with multiple closes above $63, telling traders that buyers are slowly taking control after earnings.

Intraday, the 5‑minute tape shows explosive action, with MRNA ripping from the $60s into the $120s during an extended-hours spike. That kind of range is a magnet for momentum traders. It signals heavy liquidity and strong emotion around the tape, often tied to headline risk like the new flu-vaccine approval.

Under the hood, Moderna printed about $1.94B in trailing revenue, but the latest quarter still showed a net loss of $782M and EBITDA of -$734M. Margins are deeply negative, and free cash flow ran about -$563M, even with solid gross margin near 32.3%. Balance sheet strength is the offset: more than $5.1B in cash and short-term investments, low debt (total debt-to-equity roughly 0.18), and a current ratio around 2.3.

More Breaking News

For traders, MRNA is not a value play. It is a pipeline and catalyst story, with price-to-sales over 11 and sharp swings around every data point.

Why Traders Are Watching MRNA Now

The big new driver is the FDA’s approval of Moderna’s mFLUSIVA seasonal flu vaccine for adults 50+. This is MRNA’s fourth approved product in the U.S. and its fifth globally. For a company long seen as a “COVID trade,” that matters. The new flu shot opens a fresh, recurring market for the 2026–27 respiratory season and supports ongoing reviews in Australia, Canada, and Europe. Traders see that as the mRNA platform stepping into a more durable, multi‑product phase.

At the same time, the latest Q2 2026 report showed MRNA beating consensus on both revenue and EPS, with the loss per share slightly better than feared at -$1.97 versus -$2.01 expected. Revenue ticked higher year over year, and management tightened its full‑year 2026 cost outlook, trimming cost-of-sales guidance to $1.7B and reaffirming a goal of up to 10% revenue growth off 2025. That signals more discipline even as the company stays in heavy-build mode.

The news is not all clean. A high‑profile norovirus Phase 3 trial failed to hit early success criteria, reminding traders that Moderna’s pipeline cuts both ways. But oncology and rare disease programs, including the intismeran/mRNA‑4157 cancer effort with Merck and a propionic acidemia program, remain on track with pivotal 2026 data.

Wall Street is adjusting. Citi bumped its MRNA target to $60 from $41, Goldman Sachs went to $67 from $49, and UBS also nudged its target higher, all while staying Neutral. That combination—higher targets, cautious ratings—tells traders the Street now grants more value to the non‑COVID pipeline, but still wants to see execution and a clearer route to profitability before piling in. For active trading, that gap between cautious analysts and bullish headlines often sets up sharp squeezes when news breaks in MRNA’s favor.

Conclusion

For active traders, MRNA now sits at the crossroads of story and numbers. The stock has pushed from the low‑$50s to the low‑$60s, and intraday prints show it spiking far higher on heavy volume. That reflects a market starting to price in more than just COVID boosters. With the mFLUSIVA flu vaccine approved and targeted for the 2026–27 season, MRNA has another anchor product that can diversify revenue and help justify its rich price-to-sales ratio over time.

Yet the financials remain a grind. Moderna is burning cash, carrying negative operating margins, and leaning hard into R&D at roughly $2.9B for 2026. The lowered cost-of-sales outlook and tightened guidance prove management is watching the cash runway, but traders should recognize this is still a high‑risk, pipeline-driven name. A failed norovirus trial shows how quickly sentiment can swing, while late‑stage oncology and rare disease data in 2026 could be major upside or downside catalysts for MRNA.

This is exactly the type of setup Tim Sykes loves to teach around: volatile names, clear catalysts, and a crowd chasing headlines. As Tim often says, “Patterns repeat because human nature doesn’t change—your edge is in recognizing them early and cutting losses fast.” As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.”. For MRNA, that means treating each flu‑vaccine milestone, trial result, or analyst shift as a trading catalyst, not a long-term promise—studying the chart, respecting the risk, and letting the price action confirm the story.

This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!